IDEAYA Biosciences (IDYA) Q2 2026 earnings summary

Executive summary

• Focused on precision oncology, advancing a pipeline of first-in-class therapies for genetically defined solid tumors, with lead candidate darovasertib in late-stage trials for uveal melanoma.

• Registrational OptimUM-02 trial in metastatic uveal melanoma met its primary endpoint; NDA filing underway with completion expected in H2 2026.

• Reported positive Phase 2/3 data for darovasertib, with NDA submission planned for H2 2026 and ongoing global collaborations for further development.

• Expanded clinical programs in antibody-drug conjugates (ADCs), DNA damage response, and MTAP-deficient cancers, with multiple Phase 1/2 trials underway.

• Clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 in MTAP-deleted, RAS-mutant pancreatic cancer; Phase 1 trial to start in H2 2026.

Financial highlights

• Collaboration revenue was $8.9M for Q2 2026 and $15.4M for H1 2026, up from zero in the prior year, driven by the Servier License Agreement.

• Net loss for Q2 2026 was $112.5M, up from $77.5M in Q2 2025; H1 2026 net loss was $211.0M, up from $149.7M year-over-year.

• Research and development expenses rose 41% year-over-year to $204.4M for H1 2026, reflecting increased clinical activity and milestone payments.

• Cash, cash equivalents, and marketable securities totaled $1.24B as of June 30, 2026, up from $972.9M at March 31, 2026.

• G&A expenses for Q2 2026 were $22.5M, up from $19.4M in Q1 2026.

Outlook and guidance

• Management expects continued operating losses as clinical programs advance and anticipates sufficient liquidity to fund operations for at least 12 months.

• Cash runway guidance extends into 2030 based on current operating plan.

• Plans to initiate or expand multiple registrational and combination trials in H2 2026 and 2027.

• NDA submission for darovasertib ongoing, with potential label expansion and inclusion in clinical practice guidelines.

• Multiple clinical data updates and trial initiations expected in H2 2026 and early 2027.